| __timestamp | Bausch Health Companies Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 14993000000 |
| Thursday, January 1, 2015 | 2682700000 | 14247000000 |
| Friday, January 1, 2016 | 2810000000 | 14192000000 |
| Sunday, January 1, 2017 | 2582000000 | 14997000000 |
| Monday, January 1, 2018 | 2473000000 | 16471000000 |
| Tuesday, January 1, 2019 | 2554000000 | 14369000000 |
| Wednesday, January 1, 2020 | 2367000000 | 14197000000 |
| Friday, January 1, 2021 | 2624000000 | 14886000000 |
| Saturday, January 1, 2022 | 2625000000 | 14253000000 |
| Sunday, January 1, 2023 | 2917000000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Bausch Health Companies Inc. from 2014 to 2023. Over this period, Novartis AG consistently outspent Bausch Health, with its SG&A expenses peaking at approximately $16.5 billion in 2018, a staggering 500% more than Bausch Health's highest expenditure in 2023. Interestingly, while Novartis saw a decline of about 17% in SG&A expenses from 2018 to 2023, Bausch Health experienced a 44% increase in the same timeframe. This shift highlights differing strategic priorities and market responses. As the industry faces new challenges, these financial trends offer a glimpse into the strategic maneuvers of these pharmaceutical giants.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Bausch Health Companies Inc.
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Bausch Health Companies Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.